Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
ILD
•
Diffuse Parenchymal Lung Disease
•
IPF
•
Antifibrotic
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
Related Questions
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
Does your approach to treating latent tuberculosis differ in a patient on anti-fibrotic therapy?
What are the next steps in the management of a patient admitted with an IPF exacerbation resistant to steroid therapy?
Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?
Do you perform routine interval screening for pulmonary fibrosis in individuals who have been identified through genetic testing as being at risk for developing pulmonary fibrosis but don't exhibit any signs or symptoms?
How do you approach patients with RA and severe bronchiectasis with associated findings of UIP?
When do you screen for pulmonary hypertension in ILD patients?
What is your preferred steroid sparing agent in the treatment of Sjögren associated LIP?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
